Titan Pharmaceuticals (TTNP) Competitors $5.92 +1.14 (+23.70%) Closing price 10/1/2025Extended Trading$5.92 0.00 (0.00%) As of 10/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. PMN, DARE, RNTX, CVKD, QTTB, ENLV, KZR, LPTX, XCUR, and GLTOShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Promis Neurosciences (PMN), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Cadrenal Therapeutics (CVKD), Q32 Bio (QTTB), Enlivex Therapeutics (ENLV), Kezar Life Sciences (KZR), Leap Therapeutics (LPTX), Exicure (XCUR), and Galecto (GLTO). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Promis Neurosciences Dare Bioscience Rein Therapeutics Cadrenal Therapeutics Q32 Bio Enlivex Therapeutics Kezar Life Sciences Leap Therapeutics Exicure Galecto Titan Pharmaceuticals (NASDAQ:TTNP) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Does the media favor TTNP or PMN? In the previous week, Promis Neurosciences had 3 more articles in the media than Titan Pharmaceuticals. MarketBeat recorded 4 mentions for Promis Neurosciences and 1 mentions for Titan Pharmaceuticals. Promis Neurosciences' average media sentiment score of 0.97 beat Titan Pharmaceuticals' score of 0.82 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Titan Pharmaceuticals Positive Promis Neurosciences Positive Do analysts recommend TTNP or PMN? Promis Neurosciences has a consensus price target of $4.33, suggesting a potential upside of 844.08%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is TTNP or PMN more profitable? Titan Pharmaceuticals' return on equity of -108.60% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -108.60% -95.64% Promis Neurosciences N/A -266.69%-131.59% Which has more volatility & risk, TTNP or PMN? Titan Pharmaceuticals has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Do institutionals & insiders hold more shares of TTNP or PMN? 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, TTNP or PMN? Promis Neurosciences is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan PharmaceuticalsN/AN/A-$4.71M-$2.95-2.01Promis NeurosciencesN/AN/A$2.78M-$0.21-2.19 SummaryPromis Neurosciences beats Titan Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.88M$3.35B$6.04B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-2.0121.9084.3627.24Price / SalesN/A263.75502.46196.48Price / CashN/A46.9537.5761.53Price / Book2.2210.4312.356.74Net Income-$4.71M-$52.58M$3.32B$276.59M7 Day PerformanceN/A-1.55%-1.35%-0.47%1 Month Performance33.45%12.96%8.12%7.47%1 Year Performance25.80%15.43%73.78%34.58% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.79 of 5 stars$5.93+23.7%N/A+21.5%$7.88MN/A-2.0110High Trading VolumePMNPromis Neurosciences3.4794 of 5 stars$0.56+2.8%$4.33+668.3%-54.1%$30.73MN/A-2.725DAREDare Bioscience1.8443 of 5 stars$2.25-0.2%$10.00+345.4%-41.6%$30.26M$10K-1.0530Positive NewsGap DownRNTXRein Therapeutics3.1353 of 5 stars$1.29+8.4%$10.00+675.2%N/A$30.07MN/A-0.489CVKDCadrenal Therapeutics2.2958 of 5 stars$13.71+1.3%$32.00+133.5%-2.8%$28.10MN/A-1.544QTTBQ32 Bio2.9624 of 5 stars$2.27+4.4%$12.17+437.2%-91.6%$27.63M$1.16M-0.5339Analyst ForecastENLVEnlivex Therapeutics2.8563 of 5 stars$1.13-1.2%$10.00+784.2%-23.4%$27.57MN/A-1.9670KZRKezar Life Sciences3.6953 of 5 stars$3.75-4.6%$9.00+140.0%-50.2%$27.47MN/A-0.3960Gap DownLPTXLeap Therapeutics2.6021 of 5 stars$0.66-13.4%$3.38+410.6%-73.5%$27.39MN/A-0.4240High Trading VolumeXCURExicure1.9125 of 5 stars$4.21-1.5%N/A+97.7%$27.18M$500K-1.1150GLTOGalecto0.5705 of 5 stars$21.06+467.5%$10.00-52.5%+61.0%$27.10MN/A-1.5640Analyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies Promis Neurosciences Alternatives Dare Bioscience Alternatives Rein Therapeutics Alternatives Cadrenal Therapeutics Alternatives Q32 Bio Alternatives Enlivex Therapeutics Alternatives Kezar Life Sciences Alternatives Leap Therapeutics Alternatives Exicure Alternatives Galecto Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
